In multiple myeloma, loss-of-function mutations in IRE1α and XBP1 play pro-oncogenic roles [96], suggesting that the IRE1α-XBP1 pathway acts as a tumour suppressor in some tumours. The gene discussed is XBP1; the disease is plasma cell myeloma.